Nafcillin

Nafcillin
Names
Other namesNafcillin sodium
IUPAC name
  • (2S,5R,6R)-6-[(2-ethoxy-1-naphthoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Clinical data
Drug classAntibiotic (penicillin)[1]
Main usesTreat and prevent straphylococcal infections[1]
Side effectsPain at injection site, anaphylaxis, Clostridioides difficile infection[1]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Pregnancy
category
  • US: B (No risk in non-human studies)
    Routes of
    use
    IM, IV
    External links
    AHFS/Drugs.comMonograph
    MedlinePlusa685019
    Legal
    Legal status
    • In general: ℞ (Prescription only)
    Pharmacokinetics
    Protein binding90%
    Metabolism<30% liver
    Elimination half-life0.5 hours
    ExcretionBiliary and kidney
    Chemical and physical data
    FormulaC21H22N2O5S
    Molar mass414.48 g·mol−1
    3D model (JSmol)
    SMILES
    • O=C(O)[C@@H]3N4C(=O)[C@@H](NC(=O)c2c1ccccc1ccc2OCC)[C@H]4SC3(C)C
    InChI
    • InChI=1S/C21H22N2O5S/c1-4-28-13-10-9-11-7-5-6-8-12(11)14(13)17(24)22-15-18(25)23-16(20(26)27)21(2,3)29-19(15)23/h5-10,15-16,19H,4H2,1-3H3,(H,22,24)(H,26,27)/t15-,16+,19-/m1/s1 checkY
    • Key:GPXLMGHLHQJAGZ-JTDSTZFVSA-N checkY

    Nafcillin, sold under the brand name Unipen among others, is an antibiotic used to treat and prevent straphylococcal infections.[1] This includes includes of the skin, respiratory tract, urine, and blood.[1] It is not effective against MRSA.[1] It is given by injection into a vein or muscle.[1]

    Common side effects include pain and inflammation at the site of injection.[1] Other side effects may include anaphylaxis and Clostridioides difficile infection.[1] There is no evidence of harm with use in pregnancy, though such use has not been well studied.[2] It is a beta-lactam antibiotic of the penicillin type.[1] It is penicillinase resistant.[1]

    Nafcillin was approved for medical use in the United States in 1965.[1] In the United States 10 doses of 2 grams costs about 90 USD as of 2021.[3] In 2012, out of 38 countries it was only available in one.[4]

    Medical uses

    Nafcillin is used to treat staphylococcal infections, except those caused by MRSA.[5]

    Medical guidelines recommend either nafcillin or oxacillin as the first-line treatment for staphylococcal endocarditis in people without artificial heart valves.[6]

    Dosage

    It is given at a dose of 500 to 2,000 mg every 4 to 6 hours.[1]

    Side effects

    Serious life-threatening allergic reactions can occur.

    Milder side-effects include:

    Interactions

    There is evidence that nafcillin induces cytochrome P-450 enzymes, specifically CYP2C9. Several drugs with a narrow therapeutic window, such as warfarin and nifedipine, are metabolized by CYP2C9.[8]

    Nafcillin contains salts added as stability media. These added salts could cause edema or fluid accumulation. It would be prudent to avoid this medication if there were a concern for a congestive heart failure or kidney disease.

    References

    1. 1 2 3 4 5 6 7 8 9 10 11 12 13 "Nafcillin Monograph for Professionals". Drugs.com. Archived from the original on 24 January 2021. Retrieved 11 November 2021.
    2. "Nafcillin Use During Pregnancy". Drugs.com. Archived from the original on 4 December 2020. Retrieved 11 November 2021.
    3. "Nafcillin Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 27 September 2017. Retrieved 11 November 2021.
    4. Pulcini, Céline; Bush, Karen; Craig, William A.; Frimodt-Møller, Niels; Grayson, M. Lindsay; Mouton, Johan W.; Turnidge, John; Harbarth, Stephan; Gyssens, Inge C. (15 January 2012). "Forgotten Antibiotics: An Inventory in Europe, the United States, Canada, and Australia". Clinical Infectious Diseases. 54 (2): 268–274. doi:10.1093/cid/cir838.
    5. Pham P, Bartlett JG (January 2, 2009). "Nafcillin". Point-of-Care Information Technology ABX Guide. Johns Hopkins University. Archived from the original on April 16, 2018. Retrieved August 5, 2021. Retrieved on July 10, 2009. Freely available with registration.
    6. Bonow RO, Carabello BA, Kanu C, et al. (August 2006). "ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons". Circulation. 114 (5): e84–231. doi:10.1161/CIRCULATIONAHA.106.176857. PMID 16880336.
    7. JA Mohr. (1979). Nafcillin-associated hypokalemia. JAMA
    8. Lang CC, Jamal SK, Mohamed Z, Mustafa MR, Mustafa AM, Lee TC (June 2003). "Evidence of an interaction between nifedipine and nafcillin in humans". Br J Clin Pharmacol. 55 (6): 588–90. doi:10.1046/j.1365-2125.2003.01789.x. PMC 1884262. PMID 12814453.
    Identifiers:
    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.